Publications

We work hard to attract, retain, and support the most outstanding faculty.

Filter by

Annals of the rheumatic diseases

OP0060 MACHINE LEARNING BASED BERLIN SCORING OF MAGNETIC RESONANCE IMAGES OF THE SPINE IN PATIENTS WITH ANKYLOSING SPONDYLITIS FROM THE MEASURE 1 STUDY.

2020

Authors: A. Jamaludin, R. Windsor, S. Ather, T. Kadir, A. Zisserman, J. Braun, L. S. Gensler, P. Machado, M. ?stergaard, D. Poddubnyy, T. Coroller, B. Porter, S. Mpofu, A. Readie

Annals of the rheumatic diseases

THU0395 EFFICACY OF IXEKIZUMAB ON DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND OBJECTIVE SIGNS OF INFLAMMATION, STRATIFIED BY BASELINE CRP/SACROILIAC JOINT MRI STATUS.

2020

Authors: W. P. Maksymowych, H. Marzo-Ortega, M. ?stergaard, L. S. Gensler, J. Ermann, A. Deodhar, D. Poddubnyy, D. Sandoval, R. Bolce, A. Kronbergs, S. Liu Leage, G. Doridot, V. Geneus, A. Leung, D. Adams, M. Rudwaleit

Annals of the rheumatic diseases

OP0106 SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY.

2020

Authors: J. Braun, R. Blanco, E. Dokoupilova, L. S. Gensler, A. Kivitz, S. Hall, H. Kameda, D. Poddubnyy, M. Van de Sande, D. Van der Heijde, A. Wiksten, B. Porter, H. Richards, S. Haemmerle, A. Deodhar

TO REMOVE

FRI0524 THE ACR’S RHEUMATOLOGY INFORMATICS SYSTEM FOR EFFECTIVENESS (RISE) REGISTRY SUPPORTS SMALL RHEUMATOLOGY PRACTICES FOR FEDERAL QUALITY REPORTING PROGRAM.

2020

Authors: Z. Izadi, T. Johansson, J. LI, G. Schmajuk, J. Yazdany

TO REMOVE

FRI0510 THE FREQUENCY OF CONTRACEPTION DOCUMENTATION IN WOMEN ON AND OFF TERATOGENIC ANTI-RHEUMATIC MEDICATIONS IN THE RISE REGISTRY.

2020

Authors: M. Clowse, J. LI, M. Birru Talabi, A. Eudy, G. Schmajuk

Patient education and counseling

Implications of the current COVID-19 pandemic for communication in healthcare.

2020

Authors: Rubinelli S, Myers K, Rosenbaum M, Davis D

Obstetric Anesthesia Digest

Disseminated Intravascular Coagulation and Hemorrhage After Dilation and Evacuation Abortion for Fetal Death.

2020

Authors: J.L. Kerns, A. Ti, S. Aksel, L. Lederle, A Sokoloff, J. Steinauer

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States.

2020

Authors: Fung M, Chiu CY, DeVoe C, Doernberg SB, Schwartz BS, Langelier C, Henrich TJ, Yokoe D, Davis J, Hays SR, Chandran S, Kukreja J, Ng D, Prostko J, Taylor R, Reyes K, Bainbridge E, Bond A, Chin-Hong P, Babik JM

The Journal of invasive cardiology

Differential Longitudinal Outcomes Following Percutaneous Coronary Intervention to the Left Internal Mammary Artery and Other Bypass Grafts of the LAD: Findings From the NCDR.

2020

Authors: Yeo KK, Azarbal F, Zakroysky P, Dai D, Roe M, Wojdyla D, Low R, Shunk K

JAMA internal medicine | Volume 180 of Issue 6

Severe Lung Injury Associated With Use of e-Cigarette, or Vaping, Products-California, 2019.

2020

Authors: Heinzerling A, Armatas C, Karmarkar E, Attfield K, Guo W, Wang Y, Vrdoljak G, Moezzi B, Xu D, Wagner J, Fowles J, Dean C, Cummings KJ, Wilken JA

View Abstract

Importance

Since August 2019, more than 2700 patients have been hospitalized with e-cigarette, or vaping, product use-associated lung injury (EVALI) across the United States. This report describes the outbreak in California, a state with one of the highest case counts and with a legal adult-use (recreational) cannabis market.

Objective

To present clinical characteristics and vaping product exposures of patients with EVALI in California.

Design, Setting, and Participants

Case series describing epidemiologic and laboratory data from 160 hospitalized patients with EVALI reported to the California Department of Public Health by local health departments, who received reports from treating clinicians, from August 7 through November 8, 2019.

Exposures

Standardized patient interviews were conducted to assess vaping products used, frequency of use, and method of product acquisition. Vaping products provided by a subset of patients were tested for active ingredients and other substances.

Main Outcomes and Measures

Demographic and clinical characteristics, level of care, and outcomes of hospitalization were obtained from medical record review.

Results

Among 160 patients with EVALI, 99 (62%) were male, and the median age was 27 years (range, 14-70 years). Of 156 patients with data available, 71 (46%) were admitted to an intensive care unit, and 46 (29%) required mechanical ventilation. Four in-hospital deaths occurred. Of 86 patients interviewed, 71 (83%) reported vaping tetrahydrocannabinol (THC)-containing products, 36 (43%) cannabidiol (CBD)-containing products, and 39 (47%) nicotine-containing products. Sixty-five of 87 (75%) THC-containing products were reported as obtained from informal sources, such as friends, acquaintances, or unlicensed retailers. Of 87 vaping products tested from 24 patients, 49 (56%) contained THC. Vitamin E or vitamin E acetate was found in 41 (84%) of the THC-containing products and no nicotine products.

Conclusions and Relevance

Patients' clinical outcomes and vaping behaviors, including predominant use of THC-containing products from informal sources, are similar to those reported by other states, despite California's legal recreational cannabis market. While most THC products tested contained vitamin E or vitamin E acetate, other underlying cause(s) of injury remain possible. The California Department of Public Health recommends that individuals refrain from using any vaping or e-cigarette products, particularly THC-containing products from informal sources, while this investigation is ongoing.

View on PubMed